Article
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
Blood - 14 May 2009
Hiraga Junji, Tomita Akihiro, Sugimoto Takumi, Shimada Kazuyuki, Ito Masafumi, Nakamura Shigeo, Kiyoi Hitoshi, Kinoshita Tomohiro, Naoe Tomoki
Abstract excerpt
Although rituximab is a key molecular targeting drug for CD20-positive B-cell lymphomas, resistance to rituximab has recently been recognized as a considerable problem. Here, we report that a CD20-negative phenotypic change after chemotherapies with rituximab occurs in a certain number of CD20-positive B-cell lymphoma patients. For 5 years, 124 patients with B-cell malignancies were treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.